Description
Covimectin (Ivermectin) 12 mg
Covimectin 12 mg is identified as an oral ivermectin product. Ivermectin is an established antiparasitic medicine used for certain infections caused by parasitic worms and, in some settings, ectoparasites. Verification here is based on ivermectin prescribing information and peer-reviewed medical literature.
Active Ingredient and Medicine Class
The verified active ingredient is ivermectin. It is a macrocyclic lactone and anthelmintic medicine. Regulatory labeling describes it as a semisynthetic antiparasitic agent for oral use.
Established Medical Uses
Official labeling for ivermectin tablets includes treatment of strongyloidiasis due to Strongyloides stercoralis and onchocerciasis due to Onchocerca volvulus. Peer-reviewed reviews also describe ivermectin as a standard therapy for these infections and as an option in some other parasitic diseases, but those additional uses vary by region and are not universally approved.
How It Works
Ivermectin acts on susceptible parasites by interfering with nerve and muscle function, leading to paralysis and death of the parasite. In onchocerciasis, it rapidly reduces microfilariae but has limited effect on adult worms, so its benefit is mainly through lowering the parasite burden and disease transmission.
Important Safety Information
Ivermectin should not be used in people with known hypersensitivity to the medicine or any tablet component. Important precautions are needed in patients with conditions that may increase the risk of severe reactions from parasitic die-off, especially in areas where Loa loa infection may occur. Clinically significant interactions have been reported with medicines that affect CYP3A4 and P-glycoprotein, which may alter ivermectin exposure. Safety information in the prescribing literature also emphasizes caution in patients with serious liver disease and in those taking multiple interacting medicines.
Possible Side Effects
Commonly reported side effects include dizziness, nausea, diarrhoea, abdominal discomfort, rash, pruritus and fatigue. In onchocerciasis, adverse effects may also reflect the body’s response to dying microfilariae and can include fever, itching, swelling, joint pain and eye symptoms. Rare but serious reactions have been described, including severe neurologic effects and encephalopathy in high-risk settings.
Scientific Evidence
Peer-reviewed reviews and clinical studies show that ivermectin is effective against onchocerciasis and strongyloidiasis, with rapid reduction in microfilarial load and good overall tolerability in most patients. The literature also notes that ivermectin mainly suppresses microfilariae rather than eliminating adult worms, which explains why some parasitic infections require ongoing public-health or follow-up strategies.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified health professional.
Medical Sources
- U.S. Food and Drug Administration (FDA) — STROMECTOL (ivermectin) Tablets, prescribing information
- DailyMed — Ivermectin Tablets USP, 3 mg, prescribing information
- Goa KL, McTavish D, Clissold SP. Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991.
